Tags

Type your tag names separated by a space and hit enter

Insulin-like growth factor I: a modulator of erythropoiesis in uraemic patients?
Nephrol Dial Transplant. 1992; 7(1):40-4.ND

Abstract

Anaemia is a feature almost invariably complicating chronic renal failure. Its pathophysiology is multifactorial but the most important cause is erythropoietin (Epo) deficiency. However, either no relation or even a weakly positive relation generally exists between serum immunoreactive (i) Epo and haematocrit values in uraemic anaemia, whereas in anaemias of non-renal origin the correlation is most often strongly negative. Recent evidence indicates that growth hormone also stimulates erythropoiesis. Moreover, late erythroid progenitor cells (CFU-E) require insulin and/or insulin-like growth factor I (IGF-I) for development in vitro. IGF-I has been shown to have a synergistic action with Epo. We have measured serum iEpo and IGF-I levels in 17 haemodialysis patients with severe hyperparathyroidism (mean +/- SEM serum iPTH, 988 +/- 88 pg/ml). Mean age and duration of dialysis treatment were 46.1 +/- 3.4 and 8.8 +/- 1.0 years respectively. Mean haematocrit and haemoglobin values wer 28.1 +/- 1.7% and 9.39 +/- 0.54 g/dl respectively. Mean serum iEpo and IGF-I levels were 20.3 +/- 4.7 mU/ml and 320 +/- 20 ng/ml respectively (normal values for serum iEpo and IGF-I, 17.9 +/- 6 mU/ml and 91 +/- 23 ng/ml respectively). We found that serum IGF-I concentrations were well correlated with haematocrit values (r = 0.68, n = 15, P less than 0.004) whereas serum iEpo values were not (r = 0.41, n = 12, P = 0.18). IGF-I could therefore be an important factor regulating erythropoiesis in uraemic patients, at least when associated with severe hyperparathyroidism.

Authors+Show Affiliations

Département de Néphrologie, Hôpital Necker-Enfants Malades, Paris, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

1316579

Citation

Ureña, P, et al. "Insulin-like Growth Factor I: a Modulator of Erythropoiesis in Uraemic Patients?" Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, vol. 7, no. 1, 1992, pp. 40-4.
Ureña P, Bonnardeaux A, Eckardt KU, et al. Insulin-like growth factor I: a modulator of erythropoiesis in uraemic patients? Nephrol Dial Transplant. 1992;7(1):40-4.
Ureña, P., Bonnardeaux, A., Eckardt, K. U., Kurtz, A., & Drüeke, T. B. (1992). Insulin-like growth factor I: a modulator of erythropoiesis in uraemic patients? Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, 7(1), 40-4.
Ureña P, et al. Insulin-like Growth Factor I: a Modulator of Erythropoiesis in Uraemic Patients. Nephrol Dial Transplant. 1992;7(1):40-4. PubMed PMID: 1316579.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Insulin-like growth factor I: a modulator of erythropoiesis in uraemic patients? AU - Ureña,P, AU - Bonnardeaux,A, AU - Eckardt,K U, AU - Kurtz,A, AU - Drüeke,T B, PY - 1992/1/1/pubmed PY - 1992/1/1/medline PY - 1992/1/1/entrez SP - 40 EP - 4 JF - Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association JO - Nephrol Dial Transplant VL - 7 IS - 1 N2 - Anaemia is a feature almost invariably complicating chronic renal failure. Its pathophysiology is multifactorial but the most important cause is erythropoietin (Epo) deficiency. However, either no relation or even a weakly positive relation generally exists between serum immunoreactive (i) Epo and haematocrit values in uraemic anaemia, whereas in anaemias of non-renal origin the correlation is most often strongly negative. Recent evidence indicates that growth hormone also stimulates erythropoiesis. Moreover, late erythroid progenitor cells (CFU-E) require insulin and/or insulin-like growth factor I (IGF-I) for development in vitro. IGF-I has been shown to have a synergistic action with Epo. We have measured serum iEpo and IGF-I levels in 17 haemodialysis patients with severe hyperparathyroidism (mean +/- SEM serum iPTH, 988 +/- 88 pg/ml). Mean age and duration of dialysis treatment were 46.1 +/- 3.4 and 8.8 +/- 1.0 years respectively. Mean haematocrit and haemoglobin values wer 28.1 +/- 1.7% and 9.39 +/- 0.54 g/dl respectively. Mean serum iEpo and IGF-I levels were 20.3 +/- 4.7 mU/ml and 320 +/- 20 ng/ml respectively (normal values for serum iEpo and IGF-I, 17.9 +/- 6 mU/ml and 91 +/- 23 ng/ml respectively). We found that serum IGF-I concentrations were well correlated with haematocrit values (r = 0.68, n = 15, P less than 0.004) whereas serum iEpo values were not (r = 0.41, n = 12, P = 0.18). IGF-I could therefore be an important factor regulating erythropoiesis in uraemic patients, at least when associated with severe hyperparathyroidism. SN - 0931-0509 UR - https://www.unboundmedicine.com/medline/citation/1316579/Insulin_like_growth_factor_I:_a_modulator_of_erythropoiesis_in_uraemic_patients L2 - https://core.ac.uk/reader/11555030?utm_source=linkout DB - PRIME DP - Unbound Medicine ER -